FDA Approves Xolremdi (mavorixafor) for Use in Patients with WHIM Syndrome

BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news